NAUT

Nautilus is a self-described "development stage life sciences company" that, by its own 10-K, has "not generated any revenue from our Nautilus platform or other sources since inception" and "do not have any products available for commercial sale." The revenue line is blank in every year FY2021–FY2025, while net losses have compounded (-$50.3M → -$70.8M, then -$59.0M in FY2025). The FY2025 improvement to -$59.0M is not traction — it is belt-tightening: R&D fell 18.6% to $41.1M and capex was cut ~40% to $1.28M, the signature of a company conserving cash rather than accelerating toward launch.

The balance sheet is the crux. Cash & equivalents collapsed 55.2% to just $12.4M, and total assets fell 21.3% to $191M as the company funded a -$50.7M operating cash burn. Even counting the broader $106M of current assets (cash plus marketable securities) against a ~$51M annual burn, that is roughly two years of runway before the balance sheet forces action. Management is explicit: "We expect that we will need to raise additional capital to fund our development and commercialization plans, which may not be available to us on favorable terms or at all." With 127M shares already out and the stock at $1.73, any raise on unfavorable terms means heavy dilution from a depressed price — the worst kind. The low 0.22x liabilities/equity ratio is cosmetically reassuring but irrelevant when the equity itself ($157M, down 24.8%) is being consumed and accumulated deficit sits at -$332M.